Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05634005
Other study ID # IRB_00156498
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date December 2024

Study information

Verified date October 2023
Source University of Utah
Contact Ryan Metcalf, MD
Phone 8015852010
Email ryan.metcalf@path.utah.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will not be visible to the control. Both groups still have access to information about best practices: local clinical transfusion guidelines are available and education on blood transfusion best practices will continue regardless of randomization assignment.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date December 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ordering providers that order at least one blood product in the electronic health record Exclusion Criteria: - Any individual without privileges to place an initial order for blood product(s)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Clinical Decision Support
In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).

Locations

Country Name City State
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, Carson JL, Cichutek K, De Buck E, Devine D, Fergusson D, Follea G, French C, Frey KP, Gammon R, Levy JH, Murphy MF, Ozier Y, Pavenski K, So-Osman C, Tiberghien P, Volmink J, Waters JH, Wood EM, Seifried E; ICC PBM Frankfurt 2018 Group. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA. 2019 Mar 12;321(10):983-997. doi: 10.1001/jama.2019.0554. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Number of blood components ordered that met clinical decision support alert criteria Number of blood components ordered (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of red blood cell components ordered that met clinical decision support alert criteria Number of red blood cell components ordered that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of platelet components ordered that met clinical decision support alert criteria Number of platelet components ordered that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of plasma components ordered that met clinical decision support alert criteria Number of plasma components ordered that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of cryoprecipitate component pools ordered that met clinical decision support alert criteria Number of cryoprecipitate component pools ordered that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of blood components transfused Number of blood components transfused (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Other Number of red blood cell components transfused Number of red blood cell components transfused Through study completion, an average of 12 months
Other Number of platelet components transfused Number of platelet components transfused Through study completion, an average of 12 months
Other Number of plasma components transfused Number of plasma components transfused Through study completion, an average of 12 months
Other Number of cryoprecipitate component pools transfused Number of cryoprecipitate component pools transfused Through study completion, an average of 12 months
Other Blood component cost difference between clinical decision support eligible transfusions by study arm Blood component acquisition cost difference of completed alert eligible transfusions between study arms Through study completion, an average of 12 months
Primary Number of blood components transfused that met clinical decision support alert criteria Number of blood components transfused (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Secondary Number of red blood cell components transfused that met clinical decision support alert criteria Number of red blood cell components transfused that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Secondary Number of platelet components transfused that met clinical decision support alert criteria Number of platelet components transfused that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Secondary Number of plasma components transfused that met clinical decision support alert criteria Number of plasma components transfused that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
Secondary Number of cryoprecipitate component pools transfused that met clinical decision support alert criteria Number of cryoprecipitate component pools transfused that met criteria for clinical decision support alerts to fire Through study completion, an average of 12 months
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A